FDA approve a shared REMS for all transmucosal fentanyl products
20th February 2012
The US Food and Drug Administration (FDA) have approved a shared Risk Evaluation and Mitigation Strategy (REMS) for all Transmucosal Immediate Release Fentanyl (TIRF) products. This shared program has been designed to streamline the REMS process and will allow prescribers and pharmacists to enrol in one shared REMS system for all TIRF products. The branded fentanyl products currently included are; Abstral (sublingual tablet), Actiq (lozenge), Fentora (buccal tablet), Lazanda (nasal spray), Onsolis (buccal soluble film) and Subsys (sublingual spray), the website will be available in March 2012.
- Gabapentin oral solution and enteral feeding tubes
- Cochrane review: fentanyl for neuropathic pain
- Cochrane review: hydromorphone for cancer pain
- Cochrane review: benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases
- End of life care for infants, children and young people with life-limiting conditions: planning and management
- Calling all members - please complete our satisfaction survey!
- pH testing for nasogastric tube positioning is cost effective
- Hydromorphone injection now authorized in the UK
- Patient Safety Alert: Risk of death and severe harm from error with injectable phenytoin
- PCF5+ 2016 PDF now available